XSHE
300583
Market cap391mUSD
Oct 09, Last price
13.93CNY
1D
0.94%
1Q
17.85%
IPO
-65.08%
Name
Shandong Sito Bio-technology Co Ltd
Chart & performance
P/E
—
P/S
2.60
EPS
—
Div yield, %
0.14%
Shrs. gr., 5y
1.94%
Rev. gr., 5y
-3.30%
Revenues
1.02b
+4.77%
Net income
-73m
L-17.60%
CFO
159m
-18.48%
Dividend
Jul 14, 20260.005064 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Shandong Sito Bio-technology Co., Ltd. researches, develops, and produces steroid biomedicine intermediates. Its products include 9a-hydroxyandrost, 17a-hydroxyprogesterone, 17a-hydroxy progesterone derivatives, anecort acetate, neomycin sulfate, progesterone intermediate, tylvalosin tartrate, tetraene acetate, androstenedione, bisnoralcohol, norandrostenedione, ethylene deltenone, 16ß and 16a methyl epoxide, and hexahydro-3a-methyl, as well as androsta-1,4-diene-3,17-dione and estra-4,9-diene-3,17-dione. Shandong Sito Bio-technology Co., Ltd. was founded in 2002 and is based in Heze, China.
Key people
Qi Mi
Chairman of the Board · since 2022
Fuwen Li
Chief Financial Officer · since 2019
Lianbiao Jin
General Manager
Jianyong He
Deputy General Manager · since 2023
Qingzhi Kong
Deputy General Manager
Qihui Peng
Deputy General Manager · since 2017
Lu Li
Deputy General Manager, Secretary of the Board, Director · since 2023
Xusheng Kong
Director · since 2023
Yaping Ma
Director · since 2023
Li Kang
Independent Director · since 2023
Pengfei Tu
Independent Director · since 2023
Qiming Zhang
Independent Director · since 2023
Headquarters & legal address
山东省菏泽市定陶区东外环路南段
菏泽市, SD 100000
CN
菏泽市, SD 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||